

January 27, 2022

Contents

| | |
|--|---|
| Clinical Profile Nursing Care Nursing Procedure..... | 2 |
| Lab Analytes, Panels & Other Services | 2 |
| Additions | 2 |
| Other Services Additions..... | 3 |
| Medications | 3 |
| Additions | 3 |
| Updates | 3 |
| Regimen Library | 4 |
| Additions | 4 |
| Updates | 4 |
| Renames..... | 4 |
| Removals | 5 |
| Clinical Trial Research | 5 |
| Additions | 5 |
| Updates | 5 |
| HCPCS & Billing Codes..... | 8 |

Clinical Profile Nursing Care Nursing Procedure

Health Language Inc. (HLI) created an association between CPT code 85004 and SNOMED-CT 9564003 – Complete blood count with white cell differential, automated. The creation of this relationship generated a 1:2 mapping causing an additional click for the user to select the desired billing code 85025.

Until this association can be changed within the HLI environment the following workaround is available to chart and bill CPT code 85025 with one click:

Navigate to the Nursing Care Tab | Nursing Procedure Subtab | Search for the following term: CBC w/white cell differential automated

The screenshot displays the 'Nursing Care' section of the clinical profile, specifically the 'Nursing Procedure' subtab. A search for 'cbc' has been performed, resulting in a list of procedures. The top result, 'CBC w/white cell differential automated', is marked as a favorite. The right-hand panel shows the 'Remove Procedure Name' section with a red warning icon and the text: 'CBC w/white cell differential automated - Selected Billing Code(s) : BLOOD COUNT COMPLETE AUTO&AUTO DIFRNTL WBC (85025)'. The interface also includes navigation tabs for 'Nursing Care', 'MAR', and 'Nursing Procedure', and various utility buttons like 'ALLERGIES', 'VITAL SIGNS', 'SHOW ADVERSE EVENTS', 'MEDICATION LIST', and 'SHOW ORDERS'.

Lab Analytes, Panels & Other Services

Additions

- Additional results
- Amphetamines, blood, IA
- Antibody identification comment
- APOBEC3B
- Barbiturates, blood, IA
- Benzodiazepines, blood, IA
- BIRC2
- BRD8
- Buprenorphine, blood, IA
- Carisoprodol, blood, IA
- Chromosome interpretation, Fanconi DEB
- Cocaine/Metabolite, blood, IA
- COL2A1
- COL6A3
- CSF1
- CYSLTR2
- Drug screen 16w/conf, WB
- EMILIN2
- EPC1
- EPC2
- ERCC8
- Fentanyl, blood, IA
- Gabapentin, blood, IA
- GREB1
- HLA celiac genotype panel interpretation
- KMT5C
- LeukoVanta
- LeukoVanta panel
- MAPRE1
- MBTD1
- MEAF6
- Meperidine, blood, IA

- Methadone, blood, IA
- MYBL1
- MYOD1
- Opiates, blood, IA
- Oxycodones, blood, IA
- PAK4
- PGR
- Phencyclidine, blood, IA
- Phospholipase A2 receptor (PLA2R) AB panel
- Phospholipase A2 receptor (PLA2R) AB, ELISA, RU/mL
- Phospholipase A2 receptor (PLA2R) AB, IFA
- PLCB4
- Propoxyphene, blood, IA
- RBC fragility results reviewed
- SMARCA2
- THC (marijuana) MTB, blood, IA
- Tramadol, blood, IA
- von Willebrand comment
- ZC3H7B

Other Services Additions

- RTC Virtual care clinic APP
- RTC Virtual care clinic Dietician
- RTC Virtual care clinic MD
- RTC Virtual care clinic GREAT
- RTC Virtual care clinic Social work

Medications

Additions

- ABSK061 invest Oral
- BAL0891 invest IV
- BMS-986218 invest IV
- CG-806 G3 Formulation invest Oral
- Eltanexor (KPT-8602) invest Oral
- FT538 invest IV
- FT576 invest IV
- FT596 invest IV
- GSK4381562 invest IV
- IMM2902 invest IV
- IMP9064 invest Oral
- KZR-261 invest IV
- MT-6402 invest IV
- PRT2527 invest IV
- T3011 3x10e8 pfu invest IV
- TNO155 invest Oral

Updates

Campath IV and Alemtuzumab IV 30 mg/mL: Former obsolete drug is now active.

Regimen Library

This section does not include clinical trial regimens.

Additions

| Regimen Name |
|--|
| Atezolizumab Q28D (Adjuvant NSCLC) |
| Avatrombopag Q30D (ITP) |
| Daratumumab IV + Carfilzomib D1,8,15 + Lenalidomide + Dexamethasone Q28D (C1 Split Dosing) |
| Ropeginterferon alfa-2b-njft Q14D |
| Sirolimus albumin-bound D1,8 Q21D (Malignant PEComa) |

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Anal Cancer (Parent)
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Hepatocellular Carcinoma (HCC)
- Immune Thrombocytopenia Purpura (ITP)
- Lung Cancer, Non small cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Skin
- Multiple Myeloma (MM)
- Neuroendocrine Tumor, Carcinoid (Parent)
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer
- Renal Cell Carcinoma (RCC)

Renames

| Previous Name | New Name |
|---|---|
| Carboplatin + Paclitaxel Q7D + XRT (NSCLC) (Part 1 of 2) | Paclitaxel + Carboplatin + XRT Q7D (NSCLC) |
| Carboplatin + Paclitaxel Q21D + XRT (NSCLC) (Part 2 of 2) | Paclitaxel + Carboplatin Q21D (Consolidation NSCLC) |
| Doxorubicin D1 Q21D (Soft Tissue Sarcoma) | Doxorubicin Q21D (Soft Tissue Sarcoma) |
| Leuprolide Q3M | Leuprolide Q3M (Prostate) |

| Previous Name | New Name |
|--|---|
| Nivolumab + Ipilimumab Q21D (RCC, Colon, Rectal, Neuroendocrine) | Nivolumab (3 mg/kg) + Ipilimumab (1 mg/kg) Q21D |
| Nivolumab + Ipilimumab Q21D (SCLC, Melanoma, HCC) | Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) Q21D |

Removals

- Panobinostat D1,3,5,8,10,12 + Bortezomib D1,4,8,11 + Dexamethasone D1,2,4,5,8,9,11,12 Q21D (Part 1 of 2)
- Panobinostat D1,3,5,8,10,12 + Bortezomib D1,8 + Dexamethasone D1,2,8,9 Q21D (Part 2 of 2)
- Panobinostat D1,3,5,15,17,19 + Carfilzomib D1,2,8,9,15,16 Q28D
- Panobinostat D1,3,5,15,17,19 + Lenalidomide D1-21 + Dexamethasone Q28D

Clinical Trial Research

Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

| USOR | Updated Reference Information | | |
|-------|--|--|---|
| | Updated Drug Service Order Information | | |
| | Updated Regimen Instructions | | |
| | Other Changes | | |
| 18033 | X | | <p>The following regimens are no longer available for ordering:</p> <ul style="list-style-type: none"> • USOR 18033 MGCD516 (Sitravatinib) (PO; Daily) + Nivolumab (D1,15) Q28D • USOR 18033 MGCD516 (Sitravatinib) (PO; Daily) + Nivolumab Q28D <p>The following regimens are now available for ordering:</p> <ul style="list-style-type: none"> • USOR 18033 MGCD516 (PO; Daily) + Nivolumab (D1,15) Q28D • USOR 18033 MGCD516 (PO; Daily) + Nivolumab Q28D |

| USOR | Updated Reference Information | | | |
|-------|--|---|---|---|
| | Updated Drug Service Order Information | | | |
| | Updated Regimen Instructions | | | |
| | Other Changes | | | |
| 18130 | X | X | | <p>The following regimens are no longer available for ordering:</p> <ul style="list-style-type: none"> • USOR 18130 Part 1 Expansion Corticosteroid Monotherapy • USOR 18130 Part 1 Expansion Itacitinib + Corticosteroid |
| 18183 | X | | | <p>The following regimens are no longer available for ordering:</p> <ul style="list-style-type: none"> • USOR 18183 Food Effect Cohort BAY 2416964 Single Dose Day -3 • USOR 18183 Food Effect Cohort BAY 2416964 (PO; BID) |
| 18223 | X | X | | |
| 18281 | X | X | X | <p>The following regimens are no longer available for ordering:</p> <ul style="list-style-type: none"> • USOR 18281 BA Sub-Study (G1 to G2) CG-806 (PO; BID) Q28D • USOR 18281 BA Sub-Study (G2 to G1) CG-806 (PO; BID) Q28D Q28D <p>The following regimens are now available for ordering:</p> <ul style="list-style-type: none"> • USOR 18281 G3BA Sub-Study CG-806 G3 Formulation (Cycle 1 Day -3) • USOR 18281 G3BA Sub-Study CG-806 (PO; BID) Q28D • USOR 18281 G2BA Sub-Study (G1 to G2) CG-806 (PO; BID) Q28D • USOR 18281 G2BA Sub-Study (G2 to G1) CG-806 (PO; BID) Q28D |
| 19082 | X | X | | <p>The following regimens are no longer available for ordering:</p> <ul style="list-style-type: none"> • USOR 19082 CPI-006 + Ciforadenant (PO; BID) + Pembrolizumab Q21D • USOR 19082 CPI-006 + Ciforadenant (PO; BID) Q21D • USOR 19082 CPI-006 Q21D |
| 19118 | X | | | |
| 19200 | X | | | |
| 20156 | X | X | X | |
| 20178 | X | | | |
| 20186 | X | | | |
| 20284 | X | | | |
| 20316 | X | X | X | |
| 20336 | | X | | |
| 20409 | | X | X | |

| USOR | Updated Reference Information | | | |
|-------|--|---|---|---|
| | Updated Drug Service Order Information | | | |
| | Updated Regimen Instructions | | | |
| | Other Changes | | | |
| 21225 | | | <p>The following regimen is no longer available for ordering: USOR 21225 ARX788 Q28D</p> <p>The following regimen is now available for ordering: USOR 21225 ARX788 Q21D</p> | |
| 21238 | X | X | X | <p>The following regimens are now available for ordering:</p> <ul style="list-style-type: none"> • USOR 21238 Daratumumab SQ D1,8,15 + NKTR-255 D2 Q21D (21-day schedule) (Cycle 1-2) • USOR 21238 Daratumumab SQ + NKTR-255 Q28D (Cycle 3-6) • USOR 21238 Daratumumab SQ D1,15 + NKTR-255 (Cycle 7) • USOR 21238 Daratumumab SQ + NKTR-255 (Cycle 8+) • USOR 21238 Daratumumab SQ + NKTR-255 Q28D (28-day schedule) • USOR 21238 Induction Rituximab + NKTR-255 D2 Q21D (Cycle 1-3) • USOR 21238 Maintenance Rituximab + NKTR-255 Q28D (Cycle 4-11) |
| 21242 | X | X | X | |
| 21252 | X | X | X | |
| 21273 | X | X | X | <p>The following regimens are no longer available for ordering:</p> <ul style="list-style-type: none"> • USOR 21273 Magrolimab D1 + Daratumumab IV Q28D (Cycle 3+) • USOR 21273 Magrolimab D1 + Daratumumab SQ Q28D (Cycle 3+) • USOR 21273 Magrolimab D1 + Pomalidomide D1-21 + Dexamethasone Q28D (Cycle 3+) • USOR 21273 Magrolimab D1 + Bortezomib D1,8,15,22 + Dexamethasone Q28D (Cycle 3+) <p>The following regimens are now available for ordering:</p> <ul style="list-style-type: none"> • USOR 21273 Magrolimab D1,8,15,22,29 + Carfilzomib D8,15,22 + Dexamethasone (Cycle 1) • USOR 21273 Magrolimab D1,8,15,22 + Carfilzomib D1,8,15 + Dexamethasone (Cycle 2) • USOR 21273 Magrolimab D1,15 + Carfilzomib D1,8,15 + Dexamethasone Q28D (Cycle 3+) |
| 21320 | X | | | |
| 21356 | X | | | |

HCPCS & Billing Codes

The billing unit for Pylarify* has changed from MBq to mCi effective 01/01/2022. If Pylarify* was charted on during the following date ranges (01/01/2022 - 01/27/2022) please update/redo the charting and refresh the CCR to see the updated billing code and unit on the charge capture report.

| Medication | HCPCS Code |
|---|------------------------------------|
| Antihemophilic Factor (Recomb) IV | J7192 per 1 units |
| Antihemophilic Factor VIII (B-dom truncat) IV | J7182 per 1 units |
| Antihemophilic Factor VIII (Recomb, porcine) IV | J7188 per 1 units |
| Antihemophilic Factor-VWF IV (Alphanate) | J7186 per 1 units |
| Antihemophilic Factor-VWF IV (Wilate) | J7183 per 1 units |
| Apretude (Cabotegravir) | J3490 per 600 mg |
| Avalglucosidase alfa-ngpt IV | J3590 per 100 mg |
| Factor XIII A-subunit, Recomb IV | J7181 per 1 units |
| Factor VIII Recomb, Fc Fusion Protein IV | J7205 per 1 units |
| Factor XIII IV | J7180 per 1 units |
| Leqvio (Inclisiran) | J3490 per 284 mg |
| Mirena (Levonorgestrel Intrauterine) | J7298 per 1 insert (now available) |
| Pylarify* (Piflufolostat F 18) | A9595 per 1 mCi |
| Susvimo (Ranibizumab Intravitreal) | J3590 per 100 mg |
| Tick-Borne Encephalitis Vacc IM | 90627 per 0.5 mL |
| Veklury (Remdesivir) | J0248 per 1 mg |
| von Willebrand Factor (Recomb) IV | J7179 per 1 units |
| Vyvgart (Efgartigimod alfa-fcab) | J3490 per 400 mg |